IQVIA Hlds (IQV) Stock Forecast & Price Target

IQVIA Holdings is viewed favorably because its operating backdrop is improving, with TTM net new bookings rising in each of the last four quarters, book-to-bill trending upward since 1Q25, and RFP flows up strong double digits in 2Q26, supporting expectations for upside to Revenue, EBITDA, and EPS. The company’s proprietary healthcare data, 3,000 global clinical trials, 1.2 billion longitudinal patient records, and roughly 64 petabytes of data create a durable competitive advantage in clinical development and AI, while management says win rates were up double digits as of 2Q26. Commercial Solutions also has a meaningful tailwind from 20 novel drug approvals in 3Q26, the highest since 2021, which should feed multi-year commercialization demand, while improving biotech funding, strong EBP activity, and healthy margin progression reinforce the outlook.

IQVIA Holdings is pressured by a weaker fundamental setup because its growth depends on outsourced clinical trials and commercialization activity that can be disrupted by biotech VC funding deterioration, biopharma consolidation, regulatory delays, and slower pharma spending. Operationally, the company faces execution risk from 3,000 ongoing clinical trials, patient enrollment and site-selection delays, talent shortages, and cybersecurity exposure tied to more than 1.2 billion patient records, roughly 64 petabytes of proprietary data, and about 120 billion healthcare records annually. The balance sheet also reinforces a negative view, as higher-than-industry leverage and refinancing activity point to interest expense likely moving into the low-to-mid $800 million range in 2027, while even the downside case assumes only 2% EBITDA growth in both segments.